Effectiveness of SARS-CoV-2 mRNA Vaccines for Preventing Covid-19 Hospitalizations in the United States.
COVID-19
hospitalized
immunocompromised
mRNA vaccines
vaccine effectiveness
Journal
medRxiv : the preprint server for health sciences
Titre abrégé: medRxiv
Pays: United States
ID NLM: 101767986
Informations de publication
Date de publication:
08 Jul 2021
08 Jul 2021
Historique:
pubmed:
17
7
2021
medline:
17
7
2021
entrez:
16
7
2021
Statut:
epublish
Résumé
As SARS-CoV-2 vaccination coverage increases in the United States (US), there is a need to understand the real-world effectiveness against severe Covid-19 and among people at increased risk for poor outcomes. In a multicenter case-control analysis of US adults hospitalized March 11 - May 5, 2021, we evaluated vaccine effectiveness to prevent Covid-19 hospitalizations by comparing odds of prior vaccination with an mRNA vaccine (Pfizer-BioNTech or Moderna) between cases hospitalized with Covid-19 and hospital-based controls who tested negative for SARS-CoV-2. Among 1210 participants, median age was 58 years, 22.8% were Black, 13.8% were Hispanic, and 20.6% had immunosuppression. SARS-CoV-2 lineage B.1.1.7 was most common variant (59.7% of sequenced viruses). Full vaccination (receipt of two vaccine doses ≥14 days before illness onset) had been received by 45/590 (7.6%) cases and 215/620 (34.7%) controls. Overall vaccine effectiveness was 86.9% (95% CI: 80.4 to 91.2%). Vaccine effectiveness was similar for Pfizer-BioNTech and Moderna vaccines, and highest in adults aged 18-49 years (97.3%; 95% CI: 78.9 to 99.7%). Among 45 patients with vaccine-breakthrough Covid hospitalizations, 44 (97.8%) were ≥50 years old and 20 (44.4%) had immunosuppression. Vaccine effectiveness was lower among patients with immunosuppression (59.2%; 95% CI: 11.9 to 81.1%) than without immunosuppression (91.3%; 95% CI: 85.5 to 94.7%). During March-May 2021, SARS-CoV-2 mRNA vaccines were highly effective for preventing Covid-19 hospitalizations among US adults. SARS-CoV-2 vaccination was beneficial for patients with immunosuppression, but effectiveness was lower in the immunosuppressed population.
Sections du résumé
Background
UNASSIGNED
As SARS-CoV-2 vaccination coverage increases in the United States (US), there is a need to understand the real-world effectiveness against severe Covid-19 and among people at increased risk for poor outcomes.
Methods
UNASSIGNED
In a multicenter case-control analysis of US adults hospitalized March 11 - May 5, 2021, we evaluated vaccine effectiveness to prevent Covid-19 hospitalizations by comparing odds of prior vaccination with an mRNA vaccine (Pfizer-BioNTech or Moderna) between cases hospitalized with Covid-19 and hospital-based controls who tested negative for SARS-CoV-2.
Results
UNASSIGNED
Among 1210 participants, median age was 58 years, 22.8% were Black, 13.8% were Hispanic, and 20.6% had immunosuppression. SARS-CoV-2 lineage B.1.1.7 was most common variant (59.7% of sequenced viruses). Full vaccination (receipt of two vaccine doses ≥14 days before illness onset) had been received by 45/590 (7.6%) cases and 215/620 (34.7%) controls. Overall vaccine effectiveness was 86.9% (95% CI: 80.4 to 91.2%). Vaccine effectiveness was similar for Pfizer-BioNTech and Moderna vaccines, and highest in adults aged 18-49 years (97.3%; 95% CI: 78.9 to 99.7%). Among 45 patients with vaccine-breakthrough Covid hospitalizations, 44 (97.8%) were ≥50 years old and 20 (44.4%) had immunosuppression. Vaccine effectiveness was lower among patients with immunosuppression (59.2%; 95% CI: 11.9 to 81.1%) than without immunosuppression (91.3%; 95% CI: 85.5 to 94.7%).
Conclusion
UNASSIGNED
During March-May 2021, SARS-CoV-2 mRNA vaccines were highly effective for preventing Covid-19 hospitalizations among US adults. SARS-CoV-2 vaccination was beneficial for patients with immunosuppression, but effectiveness was lower in the immunosuppressed population.
Identifiants
pubmed: 34268515
doi: 10.1101/2021.07.08.21259776
pmc: PMC8282104
pii:
doi:
Types de publication
Preprint
Langues
eng
Subventions
Organisme : NCATS NIH HHS
ID : UL1 TR002243
Pays : United States
Organisme : NCATS NIH HHS
ID : UL1 TR002369
Pays : United States
Commentaires et corrections
Type : UpdateIn
Références
J Infect Dis. 2019 Sep 13;220(8):1265-1275
pubmed: 30561689
Emerg Infect Dis. 2020 Aug;26(8):1720-1730
pubmed: 32348234
Lancet. 2020 Mar 28;395(10229):1054-1062
pubmed: 32171076
Vaccine. 2013 Jun 26;31(30):3104-9
pubmed: 23624093
Emerg Infect Dis. 2021;27(5):1477-1481
pubmed: 33900192
N Engl J Med. 2021 Feb 4;384(5):403-416
pubmed: 33378609
Ann Intern Med. 2020 May 05;172(9):577-582
pubmed: 32150748
N Engl J Med. 2017 Aug 10;377(6):534-543
pubmed: 28792867
N Engl J Med. 2020 Dec 31;383(27):2603-2615
pubmed: 33301246
MMWR Morb Mortal Wkly Rep. 2021 May 07;70(18):674-679
pubmed: 33956782
JAMA Netw Open. 2021 May 3;4(5):e218828
pubmed: 33938933
MMWR Morb Mortal Wkly Rep. 2020 Apr 17;69(15):458-464
pubmed: 32298251
MMWR Morb Mortal Wkly Rep. 2021 Apr 02;70(13):495-500
pubmed: 33793460
PLoS One. 2013 Aug 16;8(8):e71079
pubmed: 23976980
N Engl J Med. 2021 Apr 15;384(15):1412-1423
pubmed: 33626250
Ann Rheum Dis. 2021 Oct;80(10):1351-1352
pubmed: 34031032
Epidemiology. 2021 Jul 1;32(4):508-517
pubmed: 34001753
J Infect Dis. 2021 Sep 1;224(5):813-820
pubmed: 33378531
J Infect Dis. 2021 Dec 15;224(12):2035-2042
pubmed: 34013330
Clin Infect Dis. 2021 Oct 20;73(8):1459-1468
pubmed: 34014274
Nat Microbiol. 2020 Nov;5(11):1403-1407
pubmed: 32669681
Clin Infect Dis. 2021 May 4;72(9):1669-1675
pubmed: 32974644
MMWR Morb Mortal Wkly Rep. 2021 May 21;70(20):753-758
pubmed: 34014909
JAMA. 2021 Jun 1;325(21):2204-2206
pubmed: 33950155